Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer

Charlotte Elberling Almasi; Klaus Brasso; Peter Iversen; Helle Pappot; Gunilla Høyer-Hansen; Keld Danø; Ib J Christensen

doi:10.1002/pros.21306

Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer

Charlotte Elberling Almasi, Klaus Brasso, Peter Iversen, Helle Pappot, Gunilla Høyer-Hansen, Keld Danø, Ib J Christensen

52 Citations (Scopus)

Abstract

BACKGROUND: The purpose of this study was to investigate the prognostic value of different forms of the urokinase receptor, uPAR, in serum from prostate cancer (PC) patients. PATIENTS AND METHODS: The uPAR forms were measured in samples from 131 metastatic PC patients. These constituted a subset of patients included in a randomized clinical trial of treatment with total androgen blockade (TAB) versus polyestradiol phosphate (PEP). Pre-treatment serum levels of intact uPAR (uPAR(I-III)), intact plus cleaved uPAR (uPAR(I-III) + uPAR(II-III)) and domain I (uPAR(I)) were measured using time-resolved fluorescence immunoassays (TR-FIAs). RESULTS: High serum levels of each of the uPAR forms were significantly associated with short overall survival (OS). The prognostic impact was strongest in the TAB treated patients with all uPAR forms being statistically significant. In multivariate analysis, uPAR(I-III) + uPAR(II-III) was an independent prognostic factor in TAB treated patients (HR = 5.2, 95% confidence interval (CI): 2.5-10.6, P

Original language	English
Journal	Prostate
Volume	71
Issue number	8
Pages (from-to)	899-907
Number of pages	9
ISSN	0270-4137
DOIs	https://doi.org/10.1002/pros.21306
Publication status	Published - 1 Jun 2011

Keywords

Aged
Aged, 80 and over
Androgen Antagonists
Bone Neoplasms
Carcinoma
Estradiol
Humans
Male
Middle Aged
Prognosis
Prostatic Neoplasms
Randomized Controlled Trials as Topic
Receptors, Urokinase Plasminogen Activator
Retrospective Studies
Treatment Outcome

Access to Document

10.1002/pros.21306

Cite this

@article{130cdc81c99a4ae4a8f7111aec36ab54,

title = "Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer",

abstract = "BACKGROUND: The purpose of this study was to investigate the prognostic value of different forms of the urokinase receptor, uPAR, in serum from prostate cancer (PC) patients. PATIENTS AND METHODS: The uPAR forms were measured in samples from 131 metastatic PC patients. These constituted a subset of patients included in a randomized clinical trial of treatment with total androgen blockade (TAB) versus polyestradiol phosphate (PEP). Pre-treatment serum levels of intact uPAR (uPAR(I-III)), intact plus cleaved uPAR (uPAR(I-III) + uPAR(II-III)) and domain I (uPAR(I)) were measured using time-resolved fluorescence immunoassays (TR-FIAs). RESULTS: High serum levels of each of the uPAR forms were significantly associated with short overall survival (OS). The prognostic impact was strongest in the TAB treated patients with all uPAR forms being statistically significant. In multivariate analysis, uPAR(I-III) + uPAR(II-III) was an independent prognostic factor in TAB treated patients (HR = 5.2, 95% confidence interval (CI): 2.5-10.6, P ",

keywords = "Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, Carcinoma, Estradiol, Humans, Male, Middle Aged, Prognosis, Prostatic Neoplasms, Randomized Controlled Trials as Topic, Receptors, Urokinase Plasminogen Activator, Retrospective Studies, Treatment Outcome",

author = "Almasi, {Charlotte Elberling} and Klaus Brasso and Peter Iversen and Helle Pappot and Gunilla H{\o}yer-Hansen and Keld Dan{\o} and Christensen, {Ib J}",

note = "Copyright {\textcopyright} 2010 Wiley-Liss, Inc.",

year = "2011",

month = jun,

day = "1",

doi = "10.1002/pros.21306",

language = "English",

volume = "71",

pages = "899--907",

journal = "Prostate",

issn = "0270-4137",

publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",

number = "8",

}

TY - JOUR

T1 - Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer

AU - Almasi, Charlotte Elberling

AU - Brasso, Klaus

AU - Iversen, Peter

AU - Pappot, Helle

AU - Høyer-Hansen, Gunilla

AU - Danø, Keld

AU - Christensen, Ib J

PY - 2011/6/1

Y1 - 2011/6/1

N2 - BACKGROUND: The purpose of this study was to investigate the prognostic value of different forms of the urokinase receptor, uPAR, in serum from prostate cancer (PC) patients. PATIENTS AND METHODS: The uPAR forms were measured in samples from 131 metastatic PC patients. These constituted a subset of patients included in a randomized clinical trial of treatment with total androgen blockade (TAB) versus polyestradiol phosphate (PEP). Pre-treatment serum levels of intact uPAR (uPAR(I-III)), intact plus cleaved uPAR (uPAR(I-III) + uPAR(II-III)) and domain I (uPAR(I)) were measured using time-resolved fluorescence immunoassays (TR-FIAs). RESULTS: High serum levels of each of the uPAR forms were significantly associated with short overall survival (OS). The prognostic impact was strongest in the TAB treated patients with all uPAR forms being statistically significant. In multivariate analysis, uPAR(I-III) + uPAR(II-III) was an independent prognostic factor in TAB treated patients (HR = 5.2, 95% confidence interval (CI): 2.5-10.6, P

AB - BACKGROUND: The purpose of this study was to investigate the prognostic value of different forms of the urokinase receptor, uPAR, in serum from prostate cancer (PC) patients. PATIENTS AND METHODS: The uPAR forms were measured in samples from 131 metastatic PC patients. These constituted a subset of patients included in a randomized clinical trial of treatment with total androgen blockade (TAB) versus polyestradiol phosphate (PEP). Pre-treatment serum levels of intact uPAR (uPAR(I-III)), intact plus cleaved uPAR (uPAR(I-III) + uPAR(II-III)) and domain I (uPAR(I)) were measured using time-resolved fluorescence immunoassays (TR-FIAs). RESULTS: High serum levels of each of the uPAR forms were significantly associated with short overall survival (OS). The prognostic impact was strongest in the TAB treated patients with all uPAR forms being statistically significant. In multivariate analysis, uPAR(I-III) + uPAR(II-III) was an independent prognostic factor in TAB treated patients (HR = 5.2, 95% confidence interval (CI): 2.5-10.6, P

KW - Aged

KW - Aged, 80 and over

KW - Androgen Antagonists

KW - Bone Neoplasms

KW - Carcinoma

KW - Estradiol

KW - Humans

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Prostatic Neoplasms

KW - Randomized Controlled Trials as Topic

KW - Receptors, Urokinase Plasminogen Activator

KW - Retrospective Studies

KW - Treatment Outcome

U2 - 10.1002/pros.21306

DO - 10.1002/pros.21306

M3 - Journal article

C2 - 21456072

SN - 0270-4137

VL - 71

SP - 899

EP - 907

JO - Prostate

JF - Prostate

IS - 8

ER -

Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this